Sex-Related Differences in the Immune System Drive Differential Responses to Anti-PD-1 Immunotherapy
Immune checkpoint inhibitors, such as anti-PD-1 antibodies, represent a significant advancement in cancer immunotherapy, but their efficacy varies notably between individuals, influenced by complex biological systems. Recent evidence suggests that sex-related biological differences play a pivotal ro...
Saved in:
| Main Authors: | Sonja Cotra, Mohammad Kohandel, Michelle Przedborski |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2024-11-01
|
| Series: | Biomolecules |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2218-273X/14/12/1513 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Anti-cancer immunotherapy-related cardiotoxicity: preventable and treatable
by: Wu Helena T., et al.
Published: (2025-01-01) -
TIM-3 teams up with PD-1 in cancer immunotherapy: mechanisms and perspectives
by: Zhuohong Yan, et al.
Published: (2025-05-01) -
Targeting the atypical chemokine receptor 2 (Ackr2) improves the benefit of anti-PD-1 immunotherapy in melanoma mouse model
by: Muhammad Zaeem Noman, et al.
Published: (2025-12-01) -
Synergies between radiotherapy and immunotherapy: a systematic review from mechanism to clinical application
by: JingLong Jiang, et al.
Published: (2025-08-01) -
The evolution of cancer immunotherapy: a comprehensive review of its history and current perspectives
by: Sana Ahuja, et al.
Published: (2024-12-01)